News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Immunomedics, Inc. (IMMU) Presents Clinical Progress of Antibody-Drug Conjugate Programs at Conference of New York Biotechnology Association


5/30/2013 9:21:19 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

MORRIS PLAINS, N.J., May 30, 2013 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, announced that during the Company's presentation at the New York Biotechnology Association's Annual Meeting yesterday, President and CEO, Cynthia L. Sullivan, updated the audience on the progress of the antibody-drug conjugate (ADC) programs.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES